Objective-S-Adenosylhomocysteine (SAH) is a better predictor of cardiovascular disease than homocysteine is, and it has been implicated in mediating the pathogenicity of hyperhomocysteinemia in atherosclerosis via an epigenetic mechanism. However, the underlying mechanism remains unclear. Here, we tested the hypothesis whether the effect of SAH on atherosclerosis is involved in epigenetic regulation of endoplasmic reticulum stress. Approach and Results-A total of 48 apolipoprotein E-deficient mice at 8 weeks were randomly divided into 4 groups (n=12 for each group). The control group was fed a conventional diet, the adenosine dialdehyde group was fed a diet that was supplemented with the SAH hydrolase inhibitor adenosine dialdehyde, and the other 2 groups were intravenously injected with a retrovirus that expressed either SAH hydrolase short hairpin RNA or scrambled short hairpin RNA semiweekly for 16 weeks. Plasma SAH levels and atherosclerotic lesion size were significantly increased in adenosine dialdehyde and SAH hydrolase short hairpin RNA groups when compared with control group. Expression of endoplasmic reticulum stress markers glucose-regulated protein-78 and CEBP-homologous protein was significantly increased in the mice with elevated plasma SAH levels. Moreover, plasma SAH was negatively associated with a decrease in the expression of trimethylated histone H3 lysine 9 and histone methyltransferases. Chromatin immunoprecipitation assays showed a significant decrease in trimethylated histone H3 lysine 9 occupancy at the glucose-regulated protein-78 and CEBP-homologous protein promoters in mice treated with adenosine dialdehyde and SAH hydrolase short hairpin RNA when compared with control mice.
A therosclerosis is a leading cause of death worldwide.
In recent decades, numerous studies have shown that hyperhomocysteinemia is a risk factor for atherosclerosis. 1 However, several large-scale intervention studies using B vitamins and folate to lower plasma homocysteine levels have not shown an overall clinical benefit. [2] [3] [4] S-adenosylhomocysteine (SAH) is the precursor of homocysteine and is reversibly hydrolyzed to homocysteine and adenosine by SAH hydrolase (SAHH). Growing evidence has indicated that plasma SAH may be a better indicator of cardiovascular disease than homocysteine. 5, 6 Our previous cohort study also found that the plasma SAH level was a significant predictor of cardiovascular risk in coronary angiographic patients. 7 Furthermore, animal studies have shown that the plasma SAH level was also a more sensitive biomarker of atherosclerosis than homocysteine, 8 and increased plasma SAH levels could promote atherosclerosis by inducing the proliferation and migration of smooth muscle cells through an oxidative stress-extracellular signal-regulated protein kinases 1 and 2 pathway. 9 However, the effects of SAH on atherosclerosis and the underlying mechanisms remain unknown.
The pathogenesis of atherosclerosis includes a moderate inflammatory response, oxidative stress, and endoplasmic reticulum (ER) stress. 10 Recently, it has been recognized that prolonged activation of the ER stress pathway, known as the unfolded protein response, occurs during all stages of atherogenesis. 11 Several studies have indicated that this response is triggered by 3 upstream proteins: PKR-like ER kinase, activating transcription factor 6, and inositol requiring enzyme 1. By inducing the expression of X box-binding protein 1, inositol requiring enzyme 1 promotes the degradation of misfolded proteins and mRNA. In addition, activating transcription factor 6 also plays a key role in the production of chaperones that facilitate the repair process, including glucose-regulated protein-78 (GRP78). Upregulation of PKR-like ER kinase increases the levels of activating transcription factor 4 and CEBP-homologous protein (CHOP), a potent inducer of apoptosis. 12 Numerous studies have shown that homocysteine may promote atherosclerosis through the activation of ER stress. 13, 14 However, there is no direct evidence that homocysteine, and not SAH, is responsible for this effect on ER stress, and no precise mechanisms have been described.
SAH is produced as a product of methylation reactions involving S-adenosylmethionine (SAM) as the methyl donor, including the methylation of DNA, histone, and other proteins. 15 The ratio of SAM/SAH has been frequently used as an indicator of the cellular methylation potential. 16 Histones can be methylated on either lysine (K) or arginine (R) residues. Lysine residues can be monomethylated, dimethylated, or trimethylated in vivo. It has been reported that trimethylated histone H3 K4 (3meH3K4) is strongly associated with transcriptional activation, whereas 3meH3K9 is predominantly correlated with transcriptional repression. 17, 18 Production of the latter epigenetic mark is catalyzed by an increasingly large family of SET-domain-containing histone lysine methyltransferases, including G9a, Setdb1, Suv39h1, and Suv39h2. 19 Several studies have revealed that plasma SAH and homocysteine levels were significantly associated with DNA hypomethylation in atherosclerosis and vascular disease. 8, 20 Wang et al 21 also found that homocysteine inhibited vascular endothelial cell growth and p21ras methylation in the presence of adenosine. Therefore, SAH and homocysteine might affect atherosclerosis both directly and indirectly by influencing DNA methylation. Furthermore, SAM and its metabolites methylthioadenosine and SAH could inhibit lipopolysaccharide-induced proinflammatory gene expression via modulation of histone methylation, particularly by decreasing the 3meH3K4 occupancy at the promoters of proinflammatory genes. 22 In contrast, elevated levels of SAH in the liver activate the expression of ER stress genes by inhibiting histone methylation and decreasing the 3meH3K9 occupancy at the promoters of ER stress genes. 23 However, whether the mechanism underlying the effect of SAH on ER stress is involved in the modulation of histone methylation in atherosclerosis is still unclear.
Here, we elevated the plasma SAH concentration in apolipoprotein E-deficient (apoE −/− ) mice by inhibiting SAHH with the competitive inhibitor adenosine dialdehyde (ADA) or by knocking down SAHH by intravenous injection of a retrovirus expressing SAHH short hairpin RNA (shRNA). The aim of this study was to examine the effects of increased plasma SAH levels on atherosclerosis and the expression of ER stress genes and to determine whether the mechanisms of SAH-induced ER stress might be involved in the modulation of histone methylation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Dietary ADA Supplementation and Intravenous Injection of SAHH shRNA Induce Plasma SAH Accumulation in apoE −/− Mice
The body weight and food intake among the 4 groups of mice were not significantly different throughout the 16 weeks of the study. The high-density lipoprotein-cholesterol levels were significantly decreased in the ADA and SAHH shRNA groups when compared with that in the C group (22.8±6.1 and 25.5±6.9, respectively, versus 32.9±9.7 mg/dL; P<0.05), whereas the levels of total cholesterol, triglyceride, and nonhigh-density lipoprotein-cholesterol among the 4 groups were not significantly different ( Table I in the online-only Data Supplement). Dietary ADA supplementation or intravenous injection of a recombinant retrovirus expressing SAHH shRNA both resulted in a significant reduction of SAHH protein expression in the aortic tissue ( Figure 1A) . The SAHH activity of red blood cells was also significantly decreased in the ADA and SAHH shRNA groups when compared with that in the C group (1.5±1.9 and 1.3±1.5, respectively, versus 6.5±1.9 nmol/h per milligram protein; P<0.05; Figure 1B ). Furthermore, the relative SAHH mRNA levels were also decreased by 62% and 70% in the ADA and SAHH shRNA groups, respectively, compared with those in the C group ( Figure 1C ). To investigate how ADA and SAHH shRNA treatment could affect SAHH mRNA levels further, we assessed the effect of ADA and SAHH shRNA on SAHH mRNA stability and total mRNA methylation in vitro. In contrast to the control or scrambled groups, ADA (30 μmol/L) and SAHH shRNA treatment both markedly decreased the half-life of SAHH mRNA (T 1/2 =6.5 or 6.0 versus 11.2 or 11.1 hours; P<0.05; Figure 1D ). Moreover, ADA (30 μmol/L) and SAHH shRNA treatment also markedly inhibited the total mRNA methylation ( Figure I in the online-only Data Supplement), which has been shown to be associated with mRNA stability. 24, 25 As a result of SAHH downregulation, the mice in the ADA and SAHH shRNA groups had notably higher plasma SAH levels when compared with the mice in the C group (75.9±9.8 and 85.5±12.1, respectively, versus 44.5±6.8 nmol/L; P<0.05; Figure 1E ). The plasma SAM/SAH ratios in the ADA and SAHH shRNA groups were obviously reduced when compared with those in the C group (0.61±0.18 and 0.59±0.30, respectively, versus 1.23±0.29; P<0.05; Figure 1F ). The plasma SAM levels in the ADA and SAHH shRNA groups were slightly lower than in the C group, but there were no significant differences among any of the groups ( Figure 1G ). Furthermore, the shRNA short hairpin RNA January 2015 plasma tHcy levels were not significantly different among the 4 groups ( Figure 1H ).
Elevated Plasma SAH Levels Promote Atherosclerosis in apoE −/− Mice
To determine the effect of high levels of SAH on the formation of atherosclerotic lesions, sections of the aortic sinus were dissected and stained with Oil red O. After 16 weeks of feeding, advanced atherosclerotic lesions were observed in the aortic sinus in mice from all 4 groups (Figure 2A ). The aortic sinus plaque areas were significantly increased in the mice from the ADA and SAHH shRNA groups when compared with those from the control group (721375±97376 and 752300±93125, respectively, versus 433416±80041 μm 2 ; P<0.001; Figure 2B ). A correlation analysis revealed a positive correlation between the plasma SAH and the aortic sinus lesion area (r=0.690; P<0.001; Figure 2C ) and a negative correlation between the plasma SAM/SAH ratio and the aortic sinus lesion area (r=−0.768; P<0.001; Figure 2D ). However, there was no significant association between the plasma tHcy or SAM levels and the aortic sinus lesion area. Further correlation analyses within the 4 treatment groups revealed that the associations between the plasma SAH or SAM/SAH ratio and the plaque sizes were significant in each of the 4 groups (Figures II and III in the online-only Data Supplement). Moreover, the associations between SAH and plaque size in the ADA and SAHH shRNA groups were much stronger than those in the control or scrambled groups (r=0.736 and 0.756 versus r=0.601 and 0.583; all P<0.05).
Increased Plasma SAH Levels Induce ER Stress in apoE −/− Mice
Next, to explore the effects of SAH on ER stress, the expression of ER stress markers, including GRP78 and CHOP, was assessed by immunohistochemical staining in aortic sinus lesions from all 4 groups. Compared with the C or scrambled groups, stronger staining for GRP78 was observed in complex plaque lesions in mice of the ADA and SAHH shRNA groups. Semiquantitative analysis revealed ≈4-fold increase in the expression of GRP78 in the ADA and SAHH shRNA groups when compared with that in the C group ( Figure 3A) . Furthermore, we observed weak CHOP immunostaining in plaque lesions from the C or scrambled groups, but strong staining was observed in lesions in the ADA and SAHH shRNA groups. The expression of CHOP was significantly increased in the ADA and SAHH shRNA groups when compared with the that in the C group (57.13±15.21% and 68.45±17.69% versus 13.74±3.48%; P<0.05; Figure 3B ). To assess whether increased plasma SAH levels correlated with increased expression of ER stress markers further, immunoblot and real-time polymerase chain reaction analyses of total aortic tissue lysates were performed. A >4-fold increase in the protein expression of GRP78 ( Figure 3C ) and CHOP ( Figure 3D ) was observed in both the ADA and SAHH shRNA groups when compared with those in the C group. The plasma SAH levels correlated positively with the protein levels of GRP78 (r=0.747; P<0.001; Figure 3E ) and CHOP (r=0.609; P<0.01; Figure 3F ), whereas the plasma SAM/SAH ratio, an indicator of methylation capacity, correlated negatively with the protein levels of GRP78 (r=−0.538; P<0.01; Figure 3G ) and CHOP (r=−0.417; P=0.04; Figure 3H ). Furthermore, the mRNA levels of GRP78 ( Figure 3I ) and CHOP ( Figure 3J ) were also significantly increased in both the ADA and the SAHH shRNA groups when compared with those in the C group. To clarify the role of ER stress in SAH-aggravated atherogenesis and whether the inhibition of ER stress could reverse SAH-aggravated atherogenesis in apoE −/− mice further, we treated apoE −/− mice with ADA or SAHH shRNA and 4-phenyl butyric acid, a chemical chaperone that can alleviate ER stress. 26 Plaque sizes were both significantly lower in mice that received 4-phenyl butyric acid treatment than in those treated with ADA or SAHH shRNA alone (P<0.001 for both) ( Figure IV in the online-only Data Supplement). These data establish a link between ER stress and SAH-accelerated atherosclerotic lesions.
Increased Plasma SAH Levels Inhibit Histone Methylation
Because 3meH3K9 and 3meH3K4 are correlated with the transcriptional repression and activation, 17,18 respectively, to investigate the effect of SAH on histone methylation, we assessed the expression of 3meH3K9 and 3meH3K4 among the 4 groups further. Immunofluorescent staining with a specific antibody recognizing 3meH3K9 indicated a greater intensity and more positive nuclear staining in complex lesions of the aortic root in mice from the control or scrambled groups. In contrast, a weaker intensity and fewer 3meH3K9-positive cells were observed in aortic lesions from mice in the ADA and SAHH shRNA groups ( Figure 4A , left). Further analyses demonstrated that the relative fluorescence intensity of 3meH3K9 staining was significantly decreased by 79% and 81% in the ADA and SAHH shRNA groups, respectively, when compared with those in the control group (P<0.05; Figure 4A , right). Western blot analyses revealed that the level of 3meH3K9 was also decreased by 78% and 83% in the ADA and SAHH shRNA groups, respectively, when compared with those in the C group (P<0.05; Figure 4B ). However, both immunofluorescent staining and Western blot analyses with a specific antibody against 3meH3K4 revealed that there was no significant difference in the level of 3meH3K4 among the 4 groups ( Figure V in the online-only Data Supplement). Correlation analyses demonstrated that the plasma SAH concentration was negatively associated with the level of 3meH3K9 (r=−0.748; P<0.001; Figure 4C , left), whereas the plasma SAM/SAH ratio was positively correlated with the level of 3meH3K9 (r=0.591; P=0.015; Figure 4C , right). This result suggested that plasma SAH accumulation induced significant inhibition of 3meH3K9 expression but had no effect on 3meH3K4 expression.
SAH Accumulation-Induced ER Stress Is Involved in the Inhibition of Histone Methylation
To examine whether the SAH accumulation-induced ER stress is involved in the inhibition of histone methylation, we quantitatively assessed the levels of 3meH3K9 occupancy at the promoters of ER stress genes further. We used the aortic specimens from the mice with the most severe atherosclerotic lesions and the highest plasma SAH levels in each group for these analyses. We conducted chromatin immunoprecipitation assays and semiquantitative polymerase chain reaction analysis and observed that the occupancy of 3meH3K9 at the GRP78 and CHOP promoters in mice from the ADA and SAHH shRNA groups was significantly decreased when compared with the control mice (decreased by 44% and 59%, respectively, for GRP78 and by 54% and 63%, respectively, for CHOP; Figure 5A ). Correlation analyses showed that the 3meH3K9 occupancy at the GRP78 and CHOP promoters correlated negatively with the plasma SAH levels (r=−0.793; P<0.01 and r=−0.667; P<0.01, respectively; Figure 5B and 5C) and positively with the plasma SAM/SAH ratio (r=0.507; P<0.05 and r=0.641; P<0.01, respectively, Figure 5D and 5E).
The results suggested that reduced 3meH3K9 occupancy at the ER stress gene promoters because of SAH accumulation resulted in the activation of ER stress.
SAH Accumulation Inhibits Histone Methylation via the Inhibition of Histone Methyltransferases
Given that SAH is a potent inhibitor of the activity of several methyltransferases and that it also regulates the expression of methyltransferases at the transcriptional level, 15, 27, 28 we hypothesized that SAH accumulation-inhibited histone methylation might be the result of inhibition of histone methyltransferases. As expected, the total H3K9 methyltransferase activity was significantly decreased by >50% in the ADA and SAHH shRNA groups when compared with those in the control group ( Figure 6A) . Moreover, the total H3K9 methyltransferase activity was negatively associated with the SAH levels (r=−0.591; P=0.002; Figure 6B ) and positively associated with the SAM/SAH ratio (r=0.519; P=0.009; Figure 6C ). Furthermore, we examined the effect of SAH accumulation on the expression of different histone H3K9 methyltransferases, including Suv39h1, Suv39h2, G9a, and Setdb1, among which Suv39h1 mediates the trimethylation of H3K9 to 3meH3K9, and we observed that the levels of aortic Suv39h1 transcripts were significantly downregulated in the ADA and SAHH shRNA groups when compared with those in the control mice ( Figure 6D ). Furthermore, the mRNA expression of G9a, which mediates the dimethylation of H3K9 to 2meH3K9, was also significantly decreased in the ADA and SAHH shRNA groups when compared with those in the control group ( Figure 6E ), whereas the mRNA expression of the other 2 methyltransferases was similar among the 4 groups ( Figure 6F and 6G) . Correlation analyses revealed that the plasma SAH levels were negatively correlated with the expressions of Suv39h1 and G9a (r=−0.525; P<0.01 and r=−0.473; P=0.02, respectively; Figure 6H and 6I), whereas the plasma SAM/SAH ratios were positively correlated with the expression of Suv39h1 and G9a (r=0.679; P<0.001 and r=0.405; P=0.049; respectively; Figure 6J and 6K), which is consistent with the hypothesis that the expression of these enzymes plays a regulatory role in histone methylation.
To explore how SAH regulates Suv39h1 and G9a gene expression, we identified the putative Suv39h1 and G9a promoter region using the Ensembl genome browser (http://www. ensembl.org) and cloned ≈2 kb of the sequence upstream of the transcriptional start site into the pGL3-Luc vector and performed a luciferase reporter assay. After the reporter plasmid was transfected into the mouse macrophage line (RAW264.7), we treated the cells with ADA (30 μmol/L) or SAHH shRNA for 24 hours. The Suv39h1 and G9a promoter activities were increased 8-and 18-fold, respectively. However, these increases were significantly inhibited by ADA or SAHH shRNA treatment ( Figure VI in the onlineonly Data Supplement). This result consistently indicates that intracellular SAH accumulation as a result of ADA and SAHH shRNA treatment directly regulates the promoter activity of the Suv39h1 and G9a genes.
Discussion
In the present study, we first reported that elevation of plasma SAH levels in apoE −/− mice with normal plasma homocysteine levels by treatment with a SAHH inhibitor or SAHH shRNA was significantly associated with atherosclerotic lesion progression. Moreover, elevated plasma SAH levels were correlated with the increased expression of ER stress markers (GRP78 and CHOP) and the inhibition of 3meH3K9 and histone methyltransferases. A chromatin immunoprecipitation assay demonstrated that there was a decrease in the levels of 3meH3K9 at the promoter regions of ER stress genes in mice with elevated plasma SAH levels. Our results suggest that atherosclerosis promoted by elevated plasma SAH levels might be associated with the induction of ER stress via modulation of histone methylation.
In our study, we promoted SAH accumulation in vivo and in vitro by targeting SAHH using the inhibitor ADA and by SAHH shRNA interference. Our findings suggested that ADA and SAHH shRNA treatment not only decreased SAHH activity but also inhibited SAHH expression at the transcriptional level, which is consistent with a recent study. 29 Furthermore, ADA-induced suppression of SAHH mRNA may be the result of a feedback mechanism in which excess SAH suppresses SAHH expression at the transcriptional level. Because SAH is an inhibitor of mRNA-methyltransferases, excess SAH can inhibit mRNA methylation, which is associated with mRNA stability. 25 Consistently, in our study, we found that ADA and SAHH shRNA treatment significantly decreased SAHH mRNA stability and total mRNA methylation in vitro. Actually, the intracellular SAH level has a stronger effect on the epigenetic changes than the plasma SAH; the plasma SAH is derived from tissues, such as the aorta, and is simply a reflection of the intracellular pools. However, the mechanisms by which SAH is transported into and out of cells are still unclear. One possibility is that SAH might indirectly enter or exit cells by hydrolyzing to homocysteine and adenosine. Second, studies conducted with isolated rat hepatocytes have shown that SAH is not taken up by cells, but rather that it binds to acceptors on the cell surface, which may lead to the transport of SAH into the cells. 30 Third, phospholipid methylation on the plasma membrane also uses SAM as methyl donor, which is converted to SAH, indirectly leading to the transport of SAH into or out of the cells. Finally, some studies in which cells were treated directly with SAH indicate that SAH might be able to enter cells directly. 31 Although hyperhomocysteinemia is a risk factor for atherosclerosis, the inconsistent results of cohort studies and the negative results of clinical intervention trials suggest that the causal relationship between homocysteine and cardiovascular disease is still controversial. 32, 33 However, previous studies have reported that severe hyperhomocysteinemia (>100 μmol/L) accelerated the atherosclerotic progression in animal models, and administration of a superphysiological dose of homocysteine (≈1 mmol/L) increased the pathogenesis of atherosclerosis in cultured cells. [34] [35] [36] However, these results do not reflect the actual effects of moderately elevated homocysteine levels on atherosclerosis progression in clinical patients. Moreover, several studies have reported that moderately elevated plasma tHcy (≈15 μmol/L), which is similar to the physiological level in humans, had no effect on atherosclerotic lesions. 37, 38 Therefore, hyperhomocysteinemia may cause complications associated with atherosclerosis but cause this condition on its own.
In addition to homocysteine, numerous studies have shown that SAH might be a primary cause of atherosclerosis in hyperhomocysteinemia, 39 and it may be a more sensitive indicator of cardiovascular disease and atherosclerosis than homocysteine. 5 Recently, several studies have reported that renal vasodilation may not be impaired by homocysteine itself but by another factor related to methionine; furthermore, aortic endothelium-dependent relaxation was also significantly impaired in hyperhomocysteinemia mice with increased tissue levels of SAH. 40, 41 It was hypothesized that SAH might also directly impair endothelium function and promote atherosclerosis in hyperhomocysteinemia patients or animal models. However, there is no direct evidence on the relationship between SAH and atherosclerosis, and the effect of homocysteine cannot be excluded. In the current study, we first used the SAHH inhibitor ADA or SAHH shRNA to induce an animal model of chronically elevated plasma SAH levels. We found that the elevated SAH levels significantly promoted atherosclerotic progression in apoE −/− mice with normal homocysteine levels. This result indicates that the effect of SAH on atherosclerosis is independent of homocysteine, which is in consistent with our previous finding that the plasma SAH level was significantly associated with cardiovascular risk independent of plasma homocysteine levels. 7 Furthermore, in our previous study, although the plasma tHcy levels in apoE −/− mice fed on a high-methionine diet increased more than 3-fold relative to the control mice with normal tHcy levels (≈5 μmol/L), no acceleration of atherosclerotic lesion formation was observed in mice with mild hyperhomocysteinemia (≈15μmol/L). 9 In contrast, in an animal model, a just 2-fold increase in the plasma SAH levels accelerated the formation of atherosclerotic lesions, whereas a 10-fold increase in the plasma tHcy levels (≈100 μmol/L) was required to cause severe hyperhomocysteinemia and accelerated the atherosclerotic progression. 35 This result suggested that a mild elevation of the plasma SAH level is more likely to promote the development of atherosclerosis than a mild elevation of the homocysteine level, which is also consistent with the finding that plasma SAH is a more sensitive marker of cardiovascular disease than plasma homocysteine. 5 In support of this view, Valli et al 42 found that elevated serum SAH levels, but not elevated homocysteine levels, were associated with cardiovascular risk in patients with chronic kidney disease. Furthermore, Sipkens et al 43 also reported that SAH induces phosphatidylserine exposure and apoptosis in endothelial cells independently of homocysteine. Taken together, our results suggest that plasma SAH causes pathological vascular effects independently of homocysteine, and the hyperhomocysteinemia -induced vascular pathology may be mainly because of SAH accumulation.
Another interesting finding in our study is that the accumulated plasma SAH-accelerated atherosclerotic lesions were linked with the activation of ER stress. It has been demonstrated that homocysteine was shown to induce ER stress and apoptotic cell death in cultured endothelial cells and apoE −/− mice. 13, 44, 45 Several studies have demonstrated that both SAH and homocysteine could promote apoptosis of endothelial cells and induce the proliferation and migration of smooth muscle cells, which may both be involved in the induction of oxidative stress. 9, 43, 46 Therefore, there might be some similar or overlapping mechanisms underlying the effects of SAH and homocysteine on atherosclerosis. Furthermore, it is well known that elevations in plasma tHcy are highly correlated with parallel increases in plasma SAH, and a high concentration of homocysteine can also indirectly increase the intracellular SAH levels through a reversible reaction catalyzed by SAHH to promote SAH synthesis. 20, 47, 48 Although the activation of ER stress was associated with the development of atherosclerotic lesions in hyperhomocysteinemia apoE −/− mice, we cannot exclude the possible effect of elevated SAH levels because the intracellular and plasma SAH levels were unknown in previous studies. Moreover, a previous study indicated that elevated liver SAH was associated with the activation of ER stress in mice with alcoholic liver injury. 23 This result suggests that SAH may be able to induce ER stress similar to homocysteine. However, the relationship between SAH and ER stress in atherosclerosis has not been directly reported to date. In this study, we first reported that the markers of ER stress (GRP78 and CHOP) were significantly increased in the advanced lesions of mice with elevated plasma SAH when compared with the control mice. Further analyses revealed that plasma SAH was positively correlated with the expression of ER stress markers (Figure 3 ). This result suggested that ER stress could also be activated in mice with elevated SAH levels and normal homocysteine levels. Hence, we speculated that the activation of ER stress and aggravated atherosclerosis in hyperhomocysteinemia may partly be ascribed to the effect of simultaneously elevated SAH levels, but the mechanism underlying the SAH-induced ER stress is unclear.
Recently, it has been shown that epigenetic regulation of gene expression plays an important role in the development of vascular disease and attracts considerable attention. For example, dysregulation of histone methylation resulted in changes in the expression of proinflammatory genes and endothelial or inducible nitric oxide synthase genes in diabetes mellitus or vascular disease. 18, [49] [50] [51] Given that SAH is involved in all methylation reactions in the body, including DNA and histone methylation, our previous studies and those of others all demonstrated that chronic elevation of homocysteine levels results in parallel increases in intracellular or plasma SAH, which is associated with DNA hypomethylation in vascular diseases or atherosclerosis related to hyperhomocysteinemia. 8, 15, 20 Hence, these findings suggested that the epigenetic mechanism of the pathogenicity of hyperhomocysteinemia in atherosclerosis might be partly mediated by its precursor, SAH. However, the contribution of SAH-mediated histone methylation to atherosclerotic lesions remains poorly understood. In the current study, to investigate whether the effects of elevated SAH levels on ER stress and atherosclerosis are related to the mediation of histone methylation, we performed immunofluorescent staining and chromatin immunoprecipitation assays to explore the effects of SAH on histone methylation and the methylated histone occupancy at the promoters of genes related to ER stress. Our findings demonstrated that increased plasma SAH was associated with a reduction in the trimethylation of H3K9 and a decrease in the occupancy of repressive 3meH3K9 at the promoter regions of ER stress-related genes (Figures 4  and 5 ). Because 3meH3K9 is mainly associated with the transcriptional repression of genes, the SAH accumulationmediated decrease in 3meH3K9 occupancy at the promoters of ER stress genes resulted in the activation transcription of ER stress-related genes. Hence, SAH accumulation-induced ER stress may be mediated by the inhibition of 3meH3K9. In support of this concept, Esfandiari et al 23 showed that elevated hepatic SAH levels also decreased the 3meH3K9 occupancy at the promoters of ER stress-related genes in mice with alcoholic liver injury. However, Ara et al 22 reported that SAM and its metabolites or SAH could reduce 3meH3K4 occupancy at the promoters of tumor necrosis factor α or inducible nitric oxide synthase in response to lipopolysaccharide. However, in our study, we observed no effect of SAH accumulation on 3meH3K4 expression (Figure Vin the online-only Data Supplement). This discrepancy may be explained by differences in the experimental conditions, such as the use of in vitro or in vivo systems or the inflammation status. According to the evidence, we inferred that accumulated disruption of the dynamic equilibrium of activating or repressive histone methylation by SAH might induce the changes in the expression of genes related to diseases.
Moreover, SAH is a potent inhibitor of the activity of several methyltransferases and also regulates the expression of methyltransferases at the transcriptional level. For example, the elevation of SAH levels decreased the levels of O6-methylguanine DNA methyltransferase mRNA in different cell lines. 27 DZNep, an inhibitor of SAHH, indirectly regulated not only the expression of the 3meH3K27 histone methyltransferase EZH2 but also the H3K9 histone methyltransferase SETDB1 at the transcriptional level. The genes are mediated by SAH accumulation in human lung cancer cells. 28 To examine whether the inhibition of histone methylation by SAH accumulation is mediated by the inhibition of histone methyltransferases further, we assessed the total H3K9 methyltransferase activity and the mRNA expression of 4 H3K9 methyltransferases and analyzed the relationship between SAH and these enzymes. The results showed that the plasma SAH levels were negatively associated with the total H3K9 methyltransferase activity and the levels of mRNA for the H3K9 methyltransferases Suv39h1 and G9a ( Figure 6 ). Luciferase reporter assays demonstrated that SAH regulated Suv39h1 and G9a mRNA expression by inhibiting their promoter activity. Furthermore, because SAHH nuclear localization coincides with high rates of mRNA synthesis, a portion of the SAHH colocalizes with RNA polymerase II, and inhibitors of SAHH reduce both the methylation and the synthesis of poly(A)+RNA, 52, 53 Therefore, it is speculated that the inhibition of histone methyltransferase mRNA by SAH accumulation may also be mediated by the inhibition of mRNA methylation.
In conclusion, plasma SAH accumulation accelerated the progression of atherosclerosis in apoE −/− mice with normal plasma homocysteine levels, which was associated with the activation of ER stress via the inhibition of histone methylation. This finding suggests that the elevated plasma SAH levels might partly contribute to the pathogenesis of atherosclerosis with hyperhomocysteinemia, which has not been previously considered. However, the detailed mechanisms of the role of SAH in atherosclerosis and whether SAH, rather than homocysteine, is a causal risk factor for cardiovascular disease need to be further investigated.
